Sugi Predict

Sugi Predict / Compounds / SCHEMBL7513475

SCHEMBL7513475

SCHEMBL7513475

CN(C)S(=O)(=O)n1cc(-c2ccccc2)nc1C=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 5/20 0.47
▸ KDM4E B2RXH2 9/20 0.39
▸ ALDH1A1 P00352 9/20 0.39
▸ SMN1; SMN2 Q16637 5/20 0.39
▸ HPGD P15428 5/20 0.39
▸ NPC1 O15118 4/20 0.39
▸ RAB9A P51151 4/20 0.39
▸ GFER P55789 2/20 0.39
▸ KMT2A Q03164 5/20 0.37
▸ HSD17B10 Q99714 5/20 0.37
▸ MEN1 O00255 4/20 0.37
▸ TLR9 Q9NR96 1/20 0.37
▸ SCD O00767 1/20 0.36
▸ MAPT P10636 3/20 0.35
▸ PKM P14618 3/20 0.35
▸ TP53 P04637 4/20 0.35
▸ CDK5 Q00535 1/20 0.35
▸ CDK5R1 Q15078 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ CASP1 P29466 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9876372 0.83 TSHR (0.43) TSHRKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL9876370 0.83 TSHR (0.43) TSHRKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL27315765 0.79 TSHR (0.44) TSHRKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL27273855 0.78 TSHR (0.43) TSHRKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL15033450 0.77 TSHR (0.47) TSHRKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL12178890 0.76 KDM4E (0.37) TSHRKDM4EALDH1A1SMN1; SMN2KMT2A
SCHEMBL9876574 0.76 MAPT (0.33) TSHRSMN1; SMN2MAPT
SCHEMBL7509246 0.75 TSHR (0.46) TSHRKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL7519440 0.75 TSHR (0.46) TSHRKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL9521448 0.75 TSHR (0.46) TSHRKDM4EALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3318561-B1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2021-12-22 — — EP disclosed
EP-3318561-B1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2021-12-22 — — EP disclosed
US-10562916-B2 Substituted quinoxalines as PDE-10 inhibitors SUNOVION PHARMACEUTICALS, INC. (US) 2020-02-18 — — US disclosed
US-10562916-B2 Substituted quinoxalines as PDE-10 inhibitors SUNOVION PHARMACEUTICALS, INC. (US) 2020-02-18 — — US disclosed
EP-2576540-B1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2019-09-04 — — EP disclosed
EP-2576540-B1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2019-09-04 — — EP disclosed
EP-3318561-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF Sunovion Pharmaceuticals Inc. (US) 2018-05-09 — — EP disclosed
EP-3318561-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF Sunovion Pharmaceuticals Inc. (US) 2018-05-09 — — EP disclosed
US-20180037590-A1 SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS SUNOVION PHARMACEUTICALS INC. 2018-02-08 — — US disclosed
US-20180037590-A1 SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS SUNOVION PHARMACEUTICALS INC. 2018-02-08 — — US disclosed
EP-2576540-A2 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF Sunovion Pharmaceuticals Inc. (US) 2013-04-10 — — EP disclosed
WO-2011150156-A2 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-12-01 — — WO disclosed
WO-2011150156-A2 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-12-01 — — WO disclosed
EP-0298196-B1 IMIDAZOLE COMPOUNDS AND BIOCIDAL COMPOSITIONS COMPRISING THE SAME ISHIHARA SANGYO KAISHA, LTD. (JP) 1993-06-02 — — EP disclosed
CN-1016309-B BIOLOGICAL LETHAL AGENT COMPOSITION ISHIHARA SANGYO KAISHA (JP) 1992-04-22 — — CN disclosed
US-5045557-A Imidazable fungicides and use thereof SCHERING AGROCHEMICALS LTD. (GB) 1991-09-03 — — US disclosed
US-4995898-A Imidazole compounds and biocidal composition comprising the same for controlling harmful organisms ISHIHARA SANGYO KAISHA, LTD. (JP) 1991-02-26 — — US disclosed
EP-0298196-A1 Imidazole compounds and biocidal compositions comprising the same ISHIHARA SANGYO KAISHA, LTD. (JP) 1989-01-11 — — EP disclosed
CN-88101228-A Imidazolium compounds and the biocides that contains this compound that is used for controlling harmful organism — 1988-12-07 — — CN disclosed
EP-0284277-A1 Cyanoimidazole fungicides AgrEvo UK Limited (GB) 1988-09-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180037590-A1 SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS PDE10A, PDE2A, PDE3A TSHR 2306/4885KDM4E 202/4885ALDH1A1 559/4885
US-10562916-B2 Substituted quinoxalines as PDE-10 inhibitors PDE4A, PDE2A, PDE9A TSHR 2874/4885KDM4E 1397/4885ALDH1A1 1140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.